A detailed history of Bank Of America Corp transactions in 89bio, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 326,369 shares of ETNB stock, worth $3.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
326,369
Previous 408,639 20.13%
Holding current value
$3.25 Million
Previous $4.76 Million 45.04%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$7.31 - $10.9 $601,393 - $896,743
-82,270 Reduced 20.13%
326,369 $2.61 Million
Q1 2024

May 15, 2024

BUY
$8.13 - $13.77 $1.11 Million - $1.88 Million
136,740 Added 50.29%
408,639 $4.76 Million
Q4 2023

Feb 14, 2024

SELL
$6.66 - $16.03 $1.74 Million - $4.18 Million
-260,875 Reduced 48.97%
271,899 $3.04 Million
Q2 2023

Aug 14, 2023

SELL
$14.15 - $22.03 $166,333 - $258,962
-11,755 Reduced 2.16%
532,774 $10.1 Million
Q1 2023

May 12, 2023

BUY
$10.48 - $16.94 $329,753 - $533,017
31,465 Added 6.13%
544,529 $8.29 Million
Q4 2022

Feb 10, 2023

SELL
$5.52 - $12.73 $336,168 - $775,257
-60,900 Reduced 10.61%
513,064 $6.53 Million
Q3 2022

Nov 14, 2022

BUY
$3.02 - $7.0 $403,623 - $935,550
133,650 Added 30.35%
573,964 $3.32 Million
Q2 2022

Aug 12, 2022

BUY
$2.09 - $4.02 $45,279 - $87,093
21,665 Added 5.17%
440,314 $1.42 Million
Q1 2022

May 16, 2022

BUY
$3.45 - $14.99 $1.08 Million - $4.69 Million
312,587 Added 294.72%
418,649 $1.58 Million
Q4 2021

Feb 08, 2022

BUY
$11.15 - $19.66 $1.01 Million - $1.78 Million
90,417 Added 577.93%
106,062 $1.39 Million
Q3 2021

Nov 15, 2021

SELL
$14.91 - $21.31 $236,651 - $338,232
-15,872 Reduced 50.36%
15,645 $306,000
Q2 2021

Sep 13, 2021

BUY
$17.42 - $28.0 $549,026 - $882,476
31,517 New
31,517 $590,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $463M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.